Shots:

• The expanded indication approval is based on PERSPECTIVE Study assessing 183 patients with older-generation Resolute Integrity DES
• The study resulted in low rates of repeat revascularization 1.1%- cardiac death 2.2%- minimal stent thrombosis 0.06% and safe results
• Resolute Drug-Eluting Stent (DES) platform includes Resolute Onyx and Resolute Integrity DES targeted for the treatment of patients with coronary artery disease who have de novo chronic total occlusion (CTO)

Ref: Medtronic | Image: Business Daily